Straits Times Index
3,313.35 +9.69 (+0.29%) S&P 500
5,227.80 +6.38 (+0.12%) Dow
39,498.18 +66.67 (+0.17%) Nasdaq
16,421.67 +33.43 (+0.20%) Bitcoin USD
61,936.25 -706.41 (-1.13%) CMC Crypto 200
1,275.14 -16.25 (-1.26%)
Equillium, Inc. (EQ)
| Previous close | 1.5400 |
| Open | 1.5400 |
| Bid | 1.4500 x 100 |
| Ask | 1.6500 x 100 |
| Day's range | 1.4700 - 1.6100 |
| 52-week range | 0.4500 - 3.2500 |
| Volume | |
| Avg. volume | 242,077 |
| Market cap | 53.587M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Business WireEquillium Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease
LA JOLLA, Calif., May 14, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that it has surpassed the interim enrollment target for the Phase 3 EQUATOR study of itolizumab in acute graft-versus-host disease (aGVHD). Equillium expects to deliver the results of the EQUATOR interim data review to Ono during the third quarter, which will then trigger Ono’s three-mo
ZacksEquillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireEquillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
LA JOLLA, Calif., May 09, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development.
